How THC Controls Chemotherapy Nausea
THC binds to CB1 receptors in the brain's vomiting centre (area postrema and nucleus tractus solitarius), inhibiting the emetic reflex triggered by chemotherapy agents. THC also modulates serotonin signalling in pathways that convey nausea signals from the gut to the brain. Smoked or vaporised cannabis provides faster antiemetic onset than oral dronabinol, which is important when nausea prevents oral administration. Understanding THC's mechanism explains why it outperforms some conventional antiemetics for refractory CINV. OG Kush and other high-THC strains are commonly reported by cancer patients for antiemetic use. The terpene limonene has additional antiemetic properties that complement THC in full-spectrum preparations.
Clinical Evidence & Research
A 2019 systematic review of 23 RCTs found cannabinoids significantly more effective than conventional antiemetics for CINV, with a relative risk of 3.82 for complete nausea control. Dronabinol's FDA approval (1985) was based on multiple controlled trials demonstrating significant reductions in CINV frequency and severity. The FDA additionally approved nabilone (a synthetic cannabinoid) in 1985 for the same indication. A Cochrane review confirmed cannabinoids are effective antiemetics but noted that more potent modern antiemetics (5-HT3 antagonists, NK1 antagonists) have largely supplanted them as first-line agents. Cannabis remains highly relevant for refractory CINV.
Access & Patient Requirements
Dronabinol (Marinol, Syndros) is available by prescription in all US states as a Schedule III drug. State medical cannabis programmes additionally provide access to whole-plant cannabis preparations. Cancer and CINV are qualifying conditions in virtually all US medical cannabis states. California, New York, and Colorado all include cancer/CINV explicitly. In Europe, dronabinol is available by prescription in Germany and several EU countries.
Recommended Cannabis Approaches for CINV
Prophylactic dosing (before chemotherapy) is more effective than reactive dosing for CINV prevention. Vaporised cannabis provides rapid antiemetic onset within 5 minutes — crucial for acute nausea management. Oral cannabis (dronabinol or edibles) provides longer-lasting prevention but 30-90 minute onset delay. Cannabis significantly improves appetite in cancer patients, countering cachexia. Full-spectrum cannabis preparations may outperform isolated THC through the entourage effect. Pain relief effects are a valuable co-benefit for cancer patients. Anxiety relief from cannabis addresses the anticipatory anxiety that worsens CINV.